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ABSTRACT

The McGill-Thy1 APP mouse is a triple transgenic model of Alzheimer disease,
which has the mutant amyloid precursor protein to synergistically over-produce
amyloid beta plaques. These mice exhibit visuo-spatial learning impairment at 3
months of age and memory impairment at 10-13 months of age in the Morris
water maze. To extend these findings mice at 3, 5, and 7 months of age were
tested on the Barnes maze. Non-Transgenic and Transgenic mice showed
improvement during acquisition. However, 3 month and 5 month McGill Thy1APP mice showed impaired acquisition learning while 7 month showed a learning
and memory deficit compared to their Non-Transgenic counterpart. Increased
expression of McSA1immuno-labeling from 5 month to 7 month transgenic mice
was observed as well as plaque burden in the hippocampal formation. Overall,
these findings indicated a correlation between increased expression of amyloid
beta and its negative effects on visuo-spatial learning and memory using the
Barnes maze. Cognitive deficits and expression of amyloid beta findings prove
further evidence that amyloid beta correlates with behavioral impairment.
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INTRODUCTION

Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that
progressively causes problems with memory, thinking, and behavior creating a
negative impact on individuals, their families, and the healthcare system. In the
United States (US), the demographics of the general population project that
incidence and prevalence of AD will continue to escalate over the next several
decades (Brookmeyer et al 2011, Hebert et al 2003). AD is now identified as the
sixth leading cause of death in the US (Murphy et al 2013). The lack of treatment
for this disease and the rising life expectancy of the population only exacerbate
the AD crisis. This warrants ongoing research to establish greater understanding
of this devastating disease and much effort is being made to improve the ways in
which effective therapies are being developed.

Incidence and Prevalence of AD

Over the last two centuries the average life expectancy has increased due
to improvement in general healthcare, nutrition, and availability of medical care
and medicines. Additionally, an increase in the aging population in the US,
especially those of the “baby boom” generation, will dramatically increase
incidence and prevalence numbers of AD. Currently, there are approximately 5.2
million people living with AD in the US (Brookmeyer et al 2011). It is estimated
that by the year 2050 at least 959,000 new individuals will suffer from this

disease (Hebert et al 2001) and a total number of approximately 13.8 million
people will have AD (Assocation 2013). These numbers emphasize the attention
that AD research needs now in order to find preventions or treatments to
decrease the burden of this disease in the future.

Symptoms of AD

Clinical features seen in AD patients are related to cognitive dysfunction
and impairment of information processing. Learning and memory capabilities are
impaired and the ability to remember newly learned information diminishes as the
disease progresses. Other cognitive functions that decline are the speed at which
an individual learns and learning performance. More specifically, one particular
symptom that also seems to worsen as the disease progresses is the ability to
spatially navigate in one’s own environment. Spatial learning and memory is
compromised in AD patients, which can be seen as they seem to be lost in their
own environment disabling them from independent living.

Familial and Sporadic AD

Aside from age being the most dramatic risk factor (Association 2011),
several lines of evidence suggest that genes may also affect the predisposition of
AD (Bekris et al 2010, Selkoe 2000). Genetically, there are two forms of AD:
familial and sporadic. Familial AD (FAD) has an autosomal dominant pattern of
inheritance that mostly occurs at an early-onset (e.g. < 65 years of age).
2

Mutations in the amyloid precursor protein (APP), presenilin-1 (PS1), and
presenilin-2 (PS2) genes are associated with the development of FAD (Hardy
1997, Lannfelt et al 1994, Tilley et al 1998). However, mutations in these genes
are rare and account for as little as 5-10% of those with AD (Selkoe 2001). It is
hypothesized that the mutations within the APP, PS1, and PS2 genes in FAD
patients are the initial triggers to the overproduction and buildup of amyloid beta
(Aβ), a peptide crucially involved with AD.

Conversely, the sporadic form is the most common form of AD, usually
occurring in individuals at a late onset (i.e. > 65 years of age). Unlike FAD, the
factors that underlie this late-onset form of AD are less clear, but researchers
and scientists believe that risk factor genes are involved. The variant of the
apolipoprotein E gene is the most prominent known genetic risk factor associated
with the propensity to develop sporadic AD (Strittmatter et al 1993). Recently,
with use of genetic wide association studies, over 11 novel loci, which include
genes related with Aβ clearance, have been identified and linked with this lateonset form of AD. This could prove to be an invaluable tool to develop early
genetic markers for early detection of the disease with hopes of improving the
patient prognosis and treatment after diagnosis (Lambert et al 2013, Seshadri et
al 2010, Tan et al 2013).
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Pathological Changes in an AD brain

The initiation and progression of AD is very complex and, despite many
hypotheses provided, the exact etiology is still unknown. Two most noticeable
and defining pathognomies of the disease, described by Alois Alzheimer, were
extracellular senile plaques (SP) and intracellular neurofibrillary tangles (NFTs).
By mid-1980’s, it was discovered that these plaques and NFTs were primarily
composed of smaller misfolded protein aggregates. The former was composed of
Aβ

(Masters

et

al

1985),

while

the

latter

was

composed

of

the

hyperphosphorylated tau protein (Grundke-Iqbal et al 1986). Other structural and
functional hallmarks that occur include synaptic dysfunction (Nistico et al 2012),
oxidative stress (Perry et al 2002), and increased local inflammatory response
(Rogers 2008). The relationship between the pathologies is questionable, but
evidence has shown all these changes are magnified in the presence of
neurotoxic Aβ (Ferretti et al 2012, Gotz et al 2001, Masliah et al 2006,
Varadarajan et al 2000), indicating of its significant causative pathogenic factor in
AD.

AD Plaque Pathology and Aβ accumulation

As stated before, there are many alterations that occur in the brain of an
AD patient, however, plaques and their molecular subunit, the Aβ peptide, have
been the focus of much research in the AD field (Findeis 2007). Plaques that
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result from the buildup of Aβ accumulate between nerve cells resulting in a
structural

change

in

neurons

and

interfere

with

functional

neuronal

communication (Kuchibhotla et al 2008). The genesis of plaques is not well
elucidated but the accumulation of its subunit, the Aβ peptide, is considered the
earliest event in the cascade leading to AD neurodegeneration (Hardy & Selkoe
2002).

The native protein species, APP, is the stem from which Aβ is processed
(Tanzi et al 1987). The generation of Aβ occurs after a specific sequence of
enzymatic activity processes its precursor protein (Haass et al 2012). APP, a
transmembrane protein, is cleaved at two locations by two different proteases: β
secretase and γ secretase (Zhang et al 2012, Zhang et al 2011). Both β and γ
secretases act like molecular scissors that help liberate the Aβ protein. Aβ can
come in varying sizes, but the species most directly linked to AD is the Aβ that is
42 residues in length (Aβ 42) (Findeis 2007). The liberation of Aβ can potentially
occur intracellularly or extracellularly depending on the localization of APP, β,
and γ secretase (LaFerla et al 2007).

Once Aβ is generated it is prone to aggregation. Much attention has been
paid to Aβ and its early forms of aggregation called oligomers, which are soluble
clusters of misfolded monomeric Aβ. Oligomerization processes start to occur
intracellularly (Walsh et al 2000), prior its secretion from the cell (Walsh et al
2002). Evidence has shown that these oligomers are responsible for synaptic
5

dysfunction, impairment of synaptic plasticity and inhibition of long term
potentiation, all of which play a role in learning and memory processes (Haass &
Selkoe 2007, Hardy & Selkoe 2002, Lambert et al 1998, Townsend et al 2006,
Walsh et al 2002).

Plaques that result from the abnormal accumulation and the buildup of Aβ
are generated in both forms of AD (i.e. FAD and sporadic AD). Interestingly, the
differences between the forms lie in the reason for the accumulation. Contrary to
FAD, the buildup of Aβ that is seen with sporadic AD is not due to genes
responsible for processing Aβ, but risk factor genes that are responsible for the
clearing and degradation of Aβ in the brain (Lambert & Amouyel 2011). Aβdegrading enzymes, such as insulin-degrading enzyme, also aid in reduced-Aβ
levels by cleaving Aβ along different sites (Wang et al 2006). Impaired clearance
of Aβ by insulin-degrading enzyme may play a role in Aβ accumulation and
because Aβ functions as its own transcription factor, initiating its own genetic
expression (Bailey et al 2011), faulty physiology will undoubtedly lead to an
irreversibly compromised pathogenic mechanism, which will contribute to AD
pathophysiology.

Despite a few statements to the contrary, plaque pathology, and the extent
cognitive dysfunction (e.g. memory loss) do not correlate well in AD; meaning
that cognitive dysfunction is not dependent on plaque load (Colom et al 2013,
Lesne et al 2008), despite the aberrant changes that are made within the brain.
6

This leads to the indication of cognitive deficits preceding plaque deposition and
the role of Aβ in AD pathogenesis.

The Role of the Hippocampus in AD

The hippocampus is highly susceptible to Aβ deposits and is severely
affected in AD. One particularly prominent oscillation in the hippocampus is theta
frequency, which is a synchronous wave pattern with a frequency ranging 3-12
Hz. Given that the hippocampus is reputably known for playing a significant role
in information processing it has been hypothesized that theta rhythm is important
for learning and memory processes. Much evidence has supported the
association between theta rhythm and learning and memory (Kahana et al 2001,
McNaughton et al 2006). The main contribution to the functional importance of
theta, however, has been demonstrated by blocking theta which significantly
impaired learning and memory (McNaughton et al 2006, Vinogradova 1995).
Evidence has shown that Aβ induces a reduction in neuronal activity including
hippocampal theta (Balleza-Tapia et al 2010, Villette et al 2010), which may
suggest that Aβ plays a role in the impairment of any hippocampal-dependent
processes.

Thy1-APP animal model for AD

Because there is currently no known cure or effective treatment for AD,
research has focused the use of animal models to analyze the Aβ peptide related
7

to AD. Mouse models are a primary research tool used to better understand the
pathophysiology of AD because they recapitulate the main neuropathology and
cognitive deficits found with AD patients (Li et al. 2013).

For the current study, the McGill Thy1-APP animal model was used.
These homologous strains of mice over-express the human APP gene with a
double Swedish mutation, which induces increased cleavage by β secretase to
generate more Aβ 40 and Aβ 42, and an Indiana mutation to favor the production
of Aβ 42. Throughout the entirety of the study three different age groups were
used: 3 months, 5 months, and 7 months. Pre-plaque, 3-month old transgenic
(Tg) mice already display early appearance of intracellular Aβ in the pyramidal
neurons of the cerebral cortex and hippocampus and establish plaque pathology
by 6 months of age (Ferretti et al 2011) (Fig. 1). Functional, structural, and
biochemical alterations are present early in these mice, which may suggest that
similar changes occur in the early stages of AD pathology making them suitable
animal models to investigate these changes that lead to memory loss and
cognitive impairment.

8

Figure 1
Immunoreactive analysis of progressive amyloid pathology in the aging McGill-Thy1APP mice referenced from (Ferretti et al 2011). (a-c) Micrographs depict intracellular
accumulation of McSA1-immunoreactive positive material in the CA1 region of
hippocampus and cerebral cortex as early as one week of age. Intracellular McSA1immunoreactive material is displayed throughout hippocampal formation and cerebral
cortex (d-f) and is intensified by 3 months of age in the same areas (g-i). (j-l) At 6
months of age plaques confirmed by Thioflavin-S staining are detected in different
sections of the cortex. (m-o) By 10 months of age intense staining reveals neuritic
amyloid plaques (m,n) surrounding dystrophic cholinergic neurites, revealed through
double labeling (o).
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RATIONALE

Mounting evidence supports a

causal role for Aβ in

the

AD

pathophysiology, in which Aβ serves as a neurotoxic effect through abnormal
physiology within the brain. An area severely affected in AD is the hippocampus,
which is hypothesized to play a role in learning and memory through theta
rhythm. One clinical symptom seen in AD patients is the impairment of spatial
learning and memory. The current study uses the Thy1-APP mouse model, an
Aβ overproducer, which undergoes a hippocampal-dependent spatial learning
and memory task maze performance to determine if increased expression of Aβ
in the hippocampus cognitively impairs spatial learning and memory.

The Thy1-APP mouse model serves to look at AD-like amyloid pathology
from the preclinical, pre-plaque aspect of AD to be translated into a clinical
setting. Mice at 3 months, 5 months, and 7 months of age serve as relevance
needed to understand the progression of AD and recognize changes in
behavioral and cognitive abilities as they age. This information could be
transferred into clinical trials to ameliorate treatment and diagnostic strategies for
the disease.

LIMITATIONS

Transgenic animals particularly rodents such as rats and mice have been
used to study human diseases such as AD. Because AD is a human disease the
validity for an animal model to fully recapitulate the full spectrum of the disease
comes into question. To date, there is not one animal model that replicates full
AD pathology.
The aging McGill Thy1-APP animal model only offers an insight to amyloid
pathology of AD through familial mutations. Despite not mimicking the full
taupathy, it allows to restrict investigation of specific changes that occur with the
neurotoxic Aβ. As previously mentioned, the initiation and progression of AD is
very complex that can only propose the involvement of certain changes in chain
of events that occur. Allowing another variable into the equation, such as
introducing neurofibrillary tangles, will only produce complex results. The
complexities of changes that occur in the progression of AD make it difficult to
dissociate between causes of AD or that of normal aging. The understanding AD
through research is phenomenal, and it has proven the neurotoxicity of Aβ in AD,
which can be seen with treatments on hand and clinical trials that suggest we are
on the right path. Because this is a fairly new animal model, further studies would
include investigating the animal model throughout its lifespan and also study how
the rate of expression of Aβ influences these changes as well to ameliorate new
therapeutics.

PURPOSE OF STUDY

The objective of the study was aimed to demonstrate the correlation of
increased expression of Aβ in the hippocampus and the impairment of spatial
learning and memory performance using the aging Thy1-APP animal model for
preclinical AD.

The first specific aim was designed to investigate hippocampal spatial
learning and reference memory performance using the widely accepted Barnes
maze (BM) in 3 month, 5 month, and 7 month old mice. Cognitive deficits are
detected in mice at 3 months of age and in mice between the ages of 10 and 13
months using the Morris water maze (MWM), another behavioral paradigm that is
widely used for spatial learning and memory tasks (Ferretti et al 2011). However,
the maze uses the aversive stimuli of water to find an escape platform which may
induce stress-related or anxiety-related behavior affecting the performance of the
mice. It has been shown that the water maze does induce plasma corticosterone
levels, indicative of stress, when compared to BM, which may have an impact on
results (Harrison et al 2009). Moreover, mice are not natural swimmers allowing
them to adopt non-spatial strategies altering test results (Whishaw & Tomie
1996). Differing weaknesses such as cause of stress on the specimen or
olfactory cues which may skew the test results may contribute to the cause of
one instrument to be preferred over the other. Moreover, though both instruments
yield similar outcomes, they each provide unique strengths that also allow for one

to be picked over the other. When used complementarily, both tools allow for
powerful assessment of spatial learning and memory.

The current study uses the BM, a land-based hippocampal-dependent spatial
reference memory task maze, which uses the mouse’s own natural motivation to
find a small recessed chamber to escape an open platform.

The second specific aim will determine amyloid beta concentrations in the
hippocampus of the Thy1-APP mice. An immunohistochemical study was used to
reveal intra- and extracellular Aβ and to investigate the localization of Aβ in the
hippocampus of the Thy1-APP Tg mice. Immunolabeling with a specific antibody
against Aβ allowed investigating the progression of acute changes in amyloid
pathology in two additional age groups of the Thy1-APP Tg mice not studied by
Ferretti (2011).

13

HYPOTHESIS

I hypothesize that as the amount of Aβ increases in the hippocampus,
(even before established plaque formation (i.e. 3 months and 5 months)),
visuospatial learning and memory declines in this animal model for AD. This may
be associated with cognitive dysfunction seen in AD patients.

EXPERIMENTAL DESIGN

Subjects

Both male and female 3 month (NTg: n = 9; Tg: n = 6), 5 month (NTg: n =
14, Tg: n = 13), and 7 month (NTg: n = 12; Tg: n = 17) McGill Thy1-APP mice
were used throughout the entirety of the study. In a controlled environment, mice
were housed in transparent cages with bedding and in a 12-hour light/dark cycle
with lights off at 7 pm. Food and tap water were available ad libitum. All
experiments were performed during light phase. At the time of testing, mice were
examined for general health measures to ensure that they were physically able to
conduct the behavioral test. Procedures complied in accordance with the
Institutional Animal Care and Use Committees and the National Institute of
Health Guide for the Care and Use of Laboratory Animals. All efforts were made
to minimize the number of animals used.

Barnes Maze spatial learning & memory testing

The Barnes Maze is a land-based test of visuo-spatial learning and
reference memory that was first developed by Carol Barnes in 1979 (Barnes
1979, O'Leary & Brown 2009). Mice are exposed to an open circular platform (91
cm diameter) in which they try to escape to a dark recessed chamber (escape
box) located under one of 20 circular holes (~5 cm in diameter each), which are
located 2.5 cm from the edge of the maze. False escape boxes that are too small

for the mouse to enter but identical to escape box are located underneath the
remaining holes (Fig. 2). The BM uses the mouse’s natural motivation to escape
through small holes and their preference for a dark environment. Spatial cues are
located around the maze to assimilate with spatial navigation, a clinical
impairment seen in AD patients.

During testing, animals will receive weak aversive reinforcement in the
form of a buzzer (80dB) located above the maze. This will motivate the mouse to
escape the platform through to the escape box. During testing mice will be kept
in a room adjacent to the testing room. Three phases of testing will be
completed: habituation, acquisition training, and probe trial (Fig. 3). A day before
the acquisition training begin, mice will complete one habituation trial becoming
familiar with the maze and escape box environment to reduce any stressful
behavior that might be elicited during acquisition trials. During this phase the
mouse will be placed at the center of the maze under a black cylindrical
chamber. After 10 s have elapsed the chamber will be lifted and the buzzer will
be turned on allowing the mouse to explore the maze for a time span of 3 min. If
a mouse does not enter escape hole in 3 min, it will be gently guided to escape
box. After entering escape hole, the mouse will remain there for 2 min before
returning to holding cage. BM will be cleaned with 10% alcohol to avoid any intramaze odor cues. A similar protocol will be followed for acquisition training;
however, mice will only remain in the escape box for 1 min upon entering. Mice
will complete 4 days of acquisition training with 4 learning trials per day. The
16

parameters of latency, errors, path length, and search strategy will be recorded.
Latency will be defined as the amount of time it takes for the mouse to enter
escape hole.

Figure 2

The Barnes maze apparatus. The BM is a large circular platform lined with 20
equidistant holes around perimeter which uses the mouse’s natural motivation to
escape through small hole. Only one hole leads to the escape box while others
contain “false” escape underneath. Overhead buzzer and video tracking system are
not depicted.
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Errors will be defined as approaches to any holes that do not have the
escape box. Due to exploratory tendencies of the mice while performing the BM
the measures of latency and errors when the mouse first approaches the target
hole (i.e. primary latency and primary errors, respectively) will also be measured
(Harrison et al 2006). Probe trials will be used to measure short term reference
memory (24 h after last acquisition trial) and long-term reference memory (8 days
after last acquisition trial). No training will be done between probe trials (Fig. 3).
All trials will be recorded using the video recording system, HVS image 2100.

Figure 3
A table representing days at which BM will be performed. Habituation phase will be done
24 hrs. prior to the start of acquisition phase so mice may become accustomed to the
maze. In the acquisition phase, BM will be performed for 4 trials per day for 4 days so
that mice may learn the position of target box. Following this, a probe phase, reflective of
memory retention, will be performed. One trial will be performed on Day 5, 24 hrs. after
last day of acquisition phase (Day 4), for short-term memory retention. Another will be
performed one week following the first probe trial (Day 12) for long-term memory
retention. No training will be done between Day 5 and 12.
18

Perfusion and Tissue Preparation

Following behavioral testing, Tg and NTg littermate mice were deeply
anesthetized with Ketamine and transcardially perfused through left ventricle with
ice cold 0.1M PBS (pH 7.4) for 5 minutes followed by a 5 minute perfusion of
ice-cold fixative solution containing 4% paraformaldehyde and 10% picric acid
dissolved in 0.1M PBS (pH7.4). The brains were quickly removed and were
allowed to postfix in the same fixative solution overnight at 4 oC and switched to
30% sucrose diluted in 0.1M PBS for cryoprotection until brains sunk. Brains
were submerged into a freezing medium (Neg-50), and sectioned at 40 μm thick
in microtome (-20 oC). Free floating hippocampal sections were collected in PBS
and processed for immunohistochemistry.

Immunohistochemistry

Following sectioning, free floating brain sections were prepared for
localized

antigen

expression

in

which

staining

was

revealed

through

chromogenic molecular labeling. Sections were incubated with the mouse
monoclonal antibody against the human Aβ to demonstrate the Aβ aggregates in
the transgenic mice. Prior to immunostaining, brain sections were incubated in
3% H2O2 for 30 min and treated with 5% goat serum blocking solution with 0.2%
triton for 60 min to inhibit endogenous peroxidase activity and nonspecific
staining, respectively. Following this, brain sections were incubated in mouse
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anti-Aβ antibody, McSA1 (working dilution: 1:4000; 4 oC), overnight. Sections
were then incubated for 2 hrs with secondary biotinylated horse anti-mouse IgG
(working dilution: 1:300) followed by amplification with the avidin-biotin complex
(Vector laboratories Inc., Burlingame, California, USA). Chromogenic staining
were revealed using DAB method. After immunostaining, all sections were
mounted on glass slides, air-dried overnight, dehydrated in ascending
concentrations of ethanol, cleared with xylene and coverslipped with Cytoseal 60.
Digital images were the acquired through imaging microscope (Zeiss). Control
images, including exclusion of primary antibody and complete immunolabeling on
NTg tissue, were acquired applying same format used for experimental sections.

Stereology and Population estimates
Estimates of Aβ immunoreactivity were acquired through stereological counts
using an Olympus BX51 microscope (Leeds Instruments) equipped with CX 9000
camera coupled to a Dell precision 390 computer workstation with Stereo Investigator
software (Microbrightfield, Williston, VT). Contours of the hippocampal CA1 region were
determined using stereotaxic coordinates of the mouse brain (Franklin and Paxinos,
1997). Total cell numbers were estimated through the volume of the hippocampus using
stereological analysis.
An optical fractionator probe was used to determine the number of neurons at
high magnification (100X oil objective with a 1.4 numerical opening). Sections were
measured while counting and the mean section thickness was used for final calculation
of number of neurons in the hippocampus.
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Statistical Analysis

Data analysis was performed using the software package SPSS (version
19) for windows. Tests for normality were performed according to the ShapiroWilk test before statistical analysis. Levene’s test of equality of error variances
was used to test the assumption of homogeneity of variances between NTg and
Tg mice across all levels.

The learning phase (Day 1-4) of the BM was analyzed using a one-way
repeated measures ANOVA with the independent variable of days listed as the
repeated factor and genotype (NTg and Tg) as the between subjects factor. The
parameters measured (i.e. latency, errors, path length, and search strategy) are
defined as the dependent variable and are parameters used to evaluate spatial
learning and memory. Two group comparisons were done by independent t-test.
Significant differences will be determined by p ≤ 0.05. Data are presented as
mean ± standard deviation, unless otherwise stated. Error bars are S.E.M.

Sample characteristics

Tests for normality were performed according to the Shapiro-Wilk test
before statistical testing for BM learning and memory phases. Variables that
violated this assumption had a positively skewed distribution with standard
deviation proportional to the mean and were selected to be transformed via
logarithmic transformation to approximate for normal distribution. Analysis was
21

carried out on the transformed scale and then back-transformed to obtain the
geometric mean where data is represented as: mean (95% Confidence Interval).
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RESULTS

Spatial learning during acquisition phase using the Barnes Maze

The cognitive status of the McGill Thy1-APP animal model, which
presents clear evidence of functional, structural and biochemical alterations that
occur before plaque pathology starting at 1 week of age with hippocampal
intraneuronal amyloid accumulation, was next investigated. Spatial learning and
memory functions, a feature compromised in AD patients, were evaluated in 3
different cohorts (i.e. 3, 5, and 7 months), which represent different time points of
amyloid pathology, using the BM. As previously mentioned, latency, errors, path
length, and search strategy were used as a measure for evaluation of spatial
learning and memory.

Evaluation of spatial learning in 3 month old mice: Day 1-4

Following the statistical analysis run, Greenhouse-Geisser was used to
correct the one-way repeated measures ANOVA and revealed that learning
phase of the BM yielded a statistically significant difference in primary latency in
both 3 month NTg and Tg McGill Thy1-APP mice during acquisition phase,
F(2.01,26.15) = 5.38, p = 0.01, partial η2 = 0.29 (Fig. 4A). A post hoc analysis with
Bonferroni adjustment showed that primary latency decreased between 82.50 ±
11.67 sec on Day 1 to 43.41 ± 8.71 sec on Day 4, a statistically significant
decrease of 39.09 sec, p = 0.02. Primary latency was also significantly

decreased between the last two days of acquisition phase, with 64.49 ± 9.55 sec
on Day 3 and 43.41 ± 8.71 sec on Day 4, a mean difference of 21.08 sec, p <
0.01. Despite no significant interaction, a test of between genotype effects
showed that there was a statistically significant difference in primary latency
between NTg (45.69 ± 9.85 sec) and Tg (82.60 ± 12.07 sec) mice collapsed
across all four days of acquisition phase, F(1,13) = 5.61, p = 0.03, partial η2 = 0.30
(Fig. 4A).

A repeated measures ANOVA, with Greenhouse-Geisser correction,
showed that there was a significant reduction in total latency over time during
acquisition phase in NTg and Tg mice, F(2.16,28.09) = 20.54, p < 0.01, partial η2 =
0.61 (Fig. 4B). These significant reductions occurred between Day 1 (138.22 ±
11.72 sec) and the 3 remaining days that followed (Day 2: 77.89 ± 9.77 sec; Day
3: 71.45 ± 8.90 sec; Day 4: 50.20 ± 8.63 sec) and additionally between Day 3
and Day 4, all p’s < 0.05. No significant interaction had occurred between
genotype and days of training. However, a significant difference in total latency
means occurred between NTg (68.17 ± 8.44 sec) and Tg (100.71 ± 10.34 sec) 3
month old mice, regardless of time point, F(1,13) = 5.94, p = 0.03, partial η2 = 0.31
(Fig. 4B). Tg mice took a longer amount of time compared NTg mice to enter into
escape box, overall.

A significant main effect of day occurred with the remaining parameters
being measured in both NTg and Tg mice (Fig. 4C–E). The BM elicited
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significant changes in primary errors over days at which acquisition phase was
held, F(3,39) = 7.55, p < 0.01, partial η2 = 0.37, indicating that mice had learned to
use spatial cues as reference points (Fig. 4C). A reduction in primary errors
occurred between Day 1 (8.63 ± 1.06 errors) and Day 4 (3.69 ± 0.77 errors), a
statistically significant decrease of 4.94 errors, p < 0.01. With the correction of
Greenhouse-Geisser in repeated measures ANOVA, the BM also elicited
changes in total errors (F

(1.91, 24.88)

= 25.20, p < 0.01, partial η2 = 0.66) where

significant reductions occurred between Day 1 (19.04 ± 2.32 errors) and the
three remaining days that followed it (Day 2: 6.53 ± 0.87 errors; Day 3: 6.12 ±
0.95 errors; Day 4: 5.31 ± 1.81 errors), all p’s < 0.01 (Fig. 4D). A main effect of
day (F(1.91,24.81) = 28.27, p < 0.01, partial η2 = 0.69 ), with the correction of a
Greenhouse-Geisser, had shown that there was also a significant reduction in
path length from 424.87 ± 42.00 cm on Day 1 and the remaining three days of
acquisition phase with Day 2 at 180.94 ± 17.01 cm, Day 3 at 170.59 ± 17.99 cm,
and Day 4 at 157.38 ± 28.70 cm, all p’s < 0.01 (Fig. 4E). No significance was
detected between groups of these same parameters.

Although no significant differences occurred in any search strategies used
between NTg and Tg mice, analysis revealed a main effect of day in terms of
percent spatial strategy used to locate escape hole during acquisition phase,
F(3,39) = 3.96, p = 0.02, η2 = 0.23. A significant difference occurred between Day 1
(27.08 ± 5.43 %) and Day 4 (58.33 ± 8.44 %), revealing a learning component to
the maze. A low percent of random search strategy used by final acquisition day
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of training demonstrated that all mice had learned to locate the escape hole
using either spatial or serial search strategy. Random search strategy was the
least used by both mice during acquisition phase. It was used more frequently on
Day 1 which dropped to negligible levels by Day 4. By final acquisition day,
spatial search strategy was preferred among both groups (Fig. 4F).

Figure 4

Barnes maze performance of Tg and NTg 3 month age-matched littermates during
acquisition phase. Performance improved significantly over the course of training.
There was no significant day by type interaction from any parameters measured. In
contrast, there was a significant between group effect for primary latency (A) and total
latency (B). Experimental groups did not differ in primary errors, total errors, and path
length (C, D, E, respectively). Search strategy analysis revealed no significant
differences either method used to find escape hole on first visit (F).
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Evaluation of Spatial Learning in 5 Month old mice: Day 1-4

The following statistical analysis was carried out on transformed data.
Results with repeated measures ANOVA demonstrated that 5 month NTg and Tg
McGill Thy1-APP mice showed successful learning with significantly lower
primary latency (F(3,75) = 13.03, p < 0.01, partial η2 = 0.34) and total latency
(F(3,75) = 21.07, p < 0.01, partial η2 = 0.46) over the 4 days of training. Using the
post hoc Bonferroni adjustment revealed that performance using the BM elicited
a significant reduction in primary latency from Day 1 (40.36 [95% CI, 32.28 to
50.47] sec) to Day 2 (23.23 [95% CI, 18.45 to 29.24] sec), Day 1 to Day 3 (25.00
[95% CI, 19.86 to 31.48] sec), and from Day 1 to Day 4 (18.90 [95%CI, 15.03 to
23.82] sec), all p’s < 0.01 (Fig. 5A). Total latency was also significantly reduced
from Day 1 (73.28 [95%CI, 58.75 to 91.41] sec) to Day 2 (35.73 [95% CI, 26.61
to 47.97] sec), Day 1 to Day 3 (31.41 [95% CI, 24.21 to 40.74] sec), and from
Day 1 to Day 4 (25.82 [95% CI, 20.14 to 33.11] sec) regardless of genotype, all
p’s < 0.01 (Fig. 5B).

Despite a non-significant day by genotype interaction, a significant
between genotype effects in latency revealed that NTg mice had reduced primary
latency (F (1, 25) = 12.12, p < 0.01, partial η2 = 0.33) and total latency (F

(1, 25)

=

7.05, p = 0.02, partial η2 = 0.22) during days of training compared to their Tg
amyloid over-producing counterparts (Fig 5A-B). Results showed that NTg first
approached target hole on average of 19.50 [95% CI, 15.45 to 24.60] sec and

27

that Tg mice of the same age group had a longer primary latency of 34.43 [95%
CI, 27.04 to 43.85] sec collapsed throughout acquisition phase, which resulted in
a 14.93 sec difference between both genotypes. Results of total latency revealed
a similar pattern in which NTg mice (29.99 [95% CI, 23.12 to 38.90] sec) took a
fewer amount of time to escape compared to Tg mice (48.53 [95% CI, 37.33 to
63.10] sec), an 17.11 sec difference.

A repeated measures of ANOVA demonstrated that the number of primary
errors remained constant for both NTg and Tg mice while total errors significantly
decreased during the acquisition phase in both groups, F (3,75) = 9.51, p < 0.01,
partial η2 = 0.28. A post hoc Bonferroni adjustment revealed that significant total
error reductions occurred from Day 1 (15.53 ± 1.57 errors) to Day 2 (10.09 ± 1.39
errors), Day 1 to Day 3 (8.25 ± 0.86 errors), and from Day 1 to Day 4 (7.84 ±
1.04), all p’s < 0.01 (Fig. 5D). The total distance (cm) travelled to enter into
target hole during the training period was analyzed the same way as total
latency. The path length among both groups had significantly decreased along
the acquisition phase, F

(3, 75)

= 13.92, p < 0.01, partial η2 = 0.36. Significant

differences occurred between Day 1 (346.24 ± 28.53 cm) and Day 2 (229.71 ±
23.91 cm), Day 1 to Day 3 (193.22 ± 14.73 cm), and Day 1 to Day 4 (182.63 ±
14.65 cm), all p’s < 0.01 (Fig. 5E).

The search strategies that were analyzed during acquisition phase
revealed that Tg did not differ in use of the three search strategies compared to
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NTg mice. Interestingly, in both groups of mice, serial strategy was preferred
among both groups more than spatial or random strategy. Random search
strategy remained low especially at the last 3 days of acquisition phase (Fig. 5F).

Figure 5

Barnes maze performance of Tg and NTg 5 month age-matched littermates during
acquisition phase (Day 1-4). Despite no significant day by type interaction from any
parameters measured, there was a significant between group effect for primary
latency (A) and total latency (B) where Tg mice took longer to approach escape hole
and exit the maze. Experimental groups did not differ in primary errors, total errors,
and path length (C, D, and E, respectively). No differences occurred in between
search strategies used (F). Overall, BM performance improved significantly with the
exception of primary errors (C) and search strategy (F).
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Evaluation of spatial learning in 7 month old mice: Day 1-4

During training days, latency to first approach target hole (primary latency)
and enter into it (total latency) was measured in 7 month NTg and Tg mice. A
main effect of day indicated a mean improvement of both primary latency (F (3, 84)
= 28.95, p < 0.01, partial η2 = 0.51) and total latency (F (3, 84) = 32.10, p < 0.01,
partial η2 = 0.53) over the course of training in both NTg and Tg mice. Post hoc
analysis with Bonferroni adjustment revealed primary latency significantly
decreased from 43.15 [95% CI, 36.64 to 50.82] sec on Day 1 to 25.41 [95% CI,
20.94 to 30.83] sec on Day 3, p < 0.01. Significant reductions also occurred from
Day 1 to Day 4 (20.28 [95% CI, 17.26 to 23.82] sec), Day 2 (36.90 [95% CI,
32.06 to 42.46] sec) to Day 3, Day 2 to Day 4, and from Day 3 to Day 4, all p’s <
0.05 (Fig. 6A). Total latency results showed a similar pattern where significant
reductions were detected from Day 1 (99.45 ± 7.45 sec) to Day 3 (53.99 ± 5.93
sec), Day 1 to Day 4 (38.46 ± 5.27 sec), Day 2 (83.50 ± 7.80 sec) to Day 3, and
from Day 2 to Day 4, all p’s < 0.05 (Fig. 6B).

A main effect of group showed that there was a statistically significant
difference of primary latency between 7 month old NTg and Tg mice collapsed
across acquisition phase, F(1,28) = 27.61, p < 0.01, partial η2 = 0.50. NTg mice
had a geometric mean of 22.13 [95% CI, 18.45 to 26.55] sec and the Tg mice of
the same age group had a geometric mean of 40.93 [95% CI, 34.99 to 47.86]
sec, over an 18 sec mean difference (Fig. 6A). There was also a between groups
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effects of total latency (F(1,28) = 5.11, p = 0.03, partial η2 = 0.15) where NTg mice
had an average of 57.12 ± 7.81 sec while Tg mice had an average of 80.58 ±
6.83 sec indicating that Tg mice took longer to enter into the escape box during
acquisition phase (Fig. 6B).

Improvement of spatial learning tasks in both groups was also evident
through the evaluation of primary errors (F(3,84) = 8.23, p = 0.01, partial η2 = 0.23),
total errors (F(3,84) = 16.19, p < 0.01, partial η2 = 0.37), and path length (F(3,84) =
17.68, p < 0.01, partial η2 = 0.39). Significant primary error reduction occurred
from Day 1 (9.12 ± 0.69 errors) to Day 4 (6.13 ± 0.47 errors) and from Day 2
(9.36 ± 0.58 errors) to Day 4, all p’s < 0.05 (Fig. 6C). Significant total error
reductions occurred between Day 1 (17.78 ± 1.74 errors) and the last two days of
training (Day 3: 11.53 ± 1.15 errors; Day 4: 8.33 ± 0.94 errors), p < 0.01.
Additionally, reductions also occurred from Day 2 (17.57 ± 1.65 errors) to Day3
and Day 4, p < 0.01 (Fig. 6D). Path length analysis revealed a similar pattern in
which significant differences occurred from Day 1(369.71 ± 32.92 cm) to the last
two days of acquisition phase (Day 3: 229.46 ± 19.59 cm; Day 4: 184.65 ± 16.94
cm), p < 0.01. Moreover, reductions had also occurred from Day 2 (355.69 ±
31.51 cm) to Day 3 and Day 4, p’s < 0.01 (Fig. 6E). No significant main effect of
group or group by day interactions were observed during acquisition phase in
these same parameters.
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Search strategy analysis revealed that spatial strategy increased during
acquisition phase for all mice, F(3,84) = 4.36, p < 0.01, η2 = 0.14 (Fig. 6F).
Significant differences occurred from Day 2 (19.91 ± 4.15%) to Day 4 (39.82 ±
4.86%). Serial strategy was preferred among both groups to locate escape hole
more than spatial or random strategy. Similar to 3- and 5- month analysis,
random strategy was least used among both groups especially the last 3 days of
acquisition period.

Figure 6
Barnes maze performance of Tg and NTg 7 month age-matched littermates during
acquisition phase (Day 1-4). Overall, performance improved significantly over the
course of training. ANOVA with repeated measures showed that the amyloid
overproducing Tg McGill Thy1-APP mice had significantly longer primary and total
latencies (A and B, respectively) than their NTg counterparts. Despite significant
reductions with primary errors (C), total errors (D), and path length (E), no significant
differences were seen between groups. The spatial search strategy significantly
increased in both groups of mice while random search strategy remained the least
search strategy used (F).
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Probe trials: Short-term and long-term retention phase

Following the acquisition phase, which was held from Day 1-4, a probe
trail was conducted 24 hours after last training day (Day 5) and 7 days following
the first probe trail (Day 12), which are reflective of short-term and long-term
retention, respectively.

During the probe trial held on Day 5, primary latency and errors were
calculated for each age group. Independent t-test revealed primary latency and
errors to reach the target hole on Day 5 was not significantly different between 3
month or 5 month NTg and Tg mice. Interestingly, primary latency was
significantly shorter in NTg 7 month old mice (10.58 ± 5.35 sec) compared to
their Tg counterparts (38.06 ± 30.49 sec), a difference of 27.48 ± 8.94 sec,
t(17.38) = 3.64, p < 0.01 (Fig. 7A). Primary errors that were also measured
during probe 1 had revealed a similar pattern in which 7 month NTg mice had
fewer errors (3.33 ± 1.30) than Tg mice of same age group (7.00 ± 5.01), t(18.96)
= 2.46, p = 0.02 (Fig. 7B). A Chi-square test revealed no association between
group and preference for spatial search strategy to locate reference hole during
probe trial of 7 month old mice (Fig. 7C).

No significant difference in primary latency and primary errors using the BM were
observed in either age group using the independent t-test during probe 2.
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Figure 7
Probe trial evaluation of 7 month McGill-Thy1-APP NTg and Tg mice. Mean (± SEM)
(A) primary latency, (B) primary errors and (C) percentage of preferred spatial
strategy to located reference hole. * = p ≤ 0.05.
Extra- and intracellular Aβ expression characterization and distribution

Extracellular

and

intracellular

labeling

was

observed

via

mouse

monoclonal antibody, McSA1, directed against Aβ to determine Aβ cellular
expression and localization. Intracellular expression was seen in both 5 month
and 7 month Tg mice where immunoreactivity remained high throughout the CA1
and CA3 region of the hippocampus and dentate gyrus, making up hippocampal
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formation. Cellular counts were taken the hippocampus. Despite increased
expression of Aβ labeled cells in aged mice, no significant difference in cell
density was detected between 5 months (119967.34 ± 36,436.49) and 7 month
(154,142.42 ± 52,861) Tg mice, t(4) = 0.92, p = 0.41.

Presence of varying sizes of extracellular Aβ was concentrated primarily in
the CA1 region of the hippocampus and dentate gyrus, making up the
hippocampal formation. Negligible amounts of extracellular deposits greater than
50 μm, deemed as mature plaques, were observed in the CA1 region of 5 month
old mice. Most deposits less than 50 μm were localized in the dentate gyrus with
seldom expression in the CA1. Far fewer Aβ aggregates or assemblies were
observed in 5 month Tg mice compared to 7 month old mice. In the proceeding
age group studied, extracellular deposits less than 50 μm spread into subiculum
and CA3 region of hippocampus. Extracellular deposits greater than 50 μm
spread throughout the CA1 and dentate gyrus revealing increased expression of
Aβ revealing that plaques are age-dependent as the number of plaques increase
with age. Disorganized assemblies less than 50 μm of Aβ were observed
throughout the hippocampus. Interestingly, Aβ cellular expression was not
detected or observed in the CA2 region of hippocampus in both age groups.
Taken together, semi-quantitative observations of McSA1-positive labeling via
bright-field microscopy suggest increased pathological accumulation of Aβ.
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DISCUSSION

The present study explored the correlation of increased Aβ expression in the
hippocampus on spatial behavior in the transgenic mouse model of AD using the
BM. In both NTg and McGill Thy1-APP Tg mice of all age groups studied,
latency, errors, and path length performance improved significantly on spatial
learning task across the 4 days of testing indicating good spatial learning, with
the exception of primary errors in 5 month old mice.

Immunohistochemical analysis revealed that increased presence of Aβ in the
hippocampus as mice age negatively affecting higher cognitive functions of
learning and memory using the BM. Similar impairment can be seen in another
mouse model of AD where age-dependent amyloid pathology impairs visuospatial learning and memory using the same paradigm. However, these results
were not obtained until a year after the initial onset of plaques. In the current
mouse model, learning deficits are well detected at 3 months even prior to initial
plaque onset. Despite this model showing a positive correlation of plaque number
affecting memory abilities of aged Tg mice, further studies should further
investigate other deposits of Aβ (e.g. oligomers) throughout amyloid pathology in
same age groups. Insignificant increase of intracellular Aβ in the CA1 region

In the current model used, Tg mice performed worse in regards to their
latencies compared to their NTg counterparts in all age groups studied. 3 month

old Tg mice took longer to escape maze during acquisition phase revealing that
learning is impaired even prior to plaque formation (i.e. 6 months of age),
supported by Ferretti (et al. 2011). This pattern continues to stretch across 5
month and 7 month old mice where Tg had longer primary and total latency than
their NTg counterparts, despite having non-significant differences in errors
suggesting information processing of their position in the maze in regards to the
environment (i.e. spatial navigation) took longer. These results support learning
deficits on the BM and suggest that Tg McGill Thy1-APP mice are impaired at
learning visuo-spatial relationships between cues and location of escape hole.

Probe analysis reveals that memory impairments were detected as early as 7
months of age. Ferretti (et al. 2011), however, noticed a similar pattern in mice
that were 10-13 months of age. The fact that memory impairment occurred
immediately after plaque pathology has been established using the BM suggests
that something directly or indirectly linked with the process of Aβ aggregation at
this particular state of amyloid pathology in this animal model is responsible for
this happening.

This study only shows the correlation of the effects that increase Aβ has on
spatial behavior using the BM and by no means acts a direct explanation for
impairment seen in the Aβ over-producing mice. Other changes that occur in this
animal model at particular time points of Aβ pathology may suggest a chain of
events that lead to spatial behavior dysfunction. A recent study, using the same
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animal model, reveals that a selected group of genes and proteins which
represent a functional relevance to learning and memory in the hippocampus are
altered in this same age group of mice (Duran-Gonzalez, unpublished data).
Also, alterations in neuronal activity in the form of long term potentiation are
altered in the CA1 region of the hippocampus, an area that is highly vulnerable to
AD deposits. Oligomeric assemblies are expressed intracellularly in these animal
models at an early age. Further studies should investigate expression and
distribution of these assemblages throughout amyloid pathology. Increased
expression of oligomeric assemblies throughout hippocampal formation may be a
possible explanation of the effects that imbalanced homeostasis of Aβ in this
area has on spatial behavior.

Despite intense AD research, the initiation and progression of AD is not well
understood and the exact etiology of the disease is still unknown. By combining
behavioral testing with measures of long term potentiation and hippocampal
protein expression crucial to its function, the BM can be a powerful tool for
studying the neural mechanisms of spatial learning and memory. Future studies
would include testing pharmaceutical drug exposure on navigational learning,
determine whether if there is more oligomeric expression of Aβ, and analyze Aβ
expression levels in the medial septum, an area closely associated with the
generation of hippocampal theta rhythm. Septal Aβ labeling revealed
assemblage of the protein as early as 5 months of age localized close to the
medial septum (data not shown). This would draw us closer in understanding
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Aβ’s effect on spatial behavior through neuronal activity and expression of
different neuronal populations within this area known as the septohippocampal
formation (Colom 2006).

Overall, this study shows that the McGill Thy1-APP Tg mice have impaired
visuo-spatial learning at 3 months of age with the combination of learning and
memory impairment at 7 months of age. This deficit in cognition was reliably
detected using measures of learning and memory. The impairment was modest
indicating that Tg mice in each age group did learn the location of escape hole
but not as well as NTg mice. Results from this data support the notion that
increased Aβ load is correlated with learning and memory impairment, even prior
to the stage where plaques are visible. This could provide a valuable
comprehensive evaluation and information on the assessment of preclinical AD.
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